The spectrum of systemic sclerosis-associated pulmonary hypertension: Insights from the ASPIRE registry

被引:0
作者
Smith, Howard [1 ]
Thompson, A. A. Roger [1 ,2 ]
Akil, Mohammed [3 ]
Alabed, Samer [4 ]
Charalampopoulos, Athanasios [1 ]
Dwivedi, Krit [4 ]
Elliot, Charlie A. [1 ]
Hameed, Abdul [1 ,2 ]
Haque, Ashraful [3 ]
Hamilton, Neil [1 ]
Hill, Catherine [4 ]
Hurdman, Judith [1 ]
Kilding, Rachael [3 ]
Kuet, Kar-Ping [3 ]
Rajaram, Smitha [4 ]
Rothman, Alexander M. K. [1 ,2 ,6 ]
Swift, Andrew J. [4 ,5 ,6 ]
Wild, James M. [4 ,5 ,6 ]
Kiely, David G. [1 ,2 ,5 ,6 ]
Condliffe, Robin [1 ,2 ]
机构
[1] Royal Hallamshire Hosp, Sheffield Pulm Vasc Dis Unit, Sheffield, England
[2] Univ Sheffield, Sch Med & Populat Hlth, Div Clin Med, Sheffield, England
[3] Royal Hallamshire Hosp, Dept Rheumatol, Sheffield, England
[4] Royal Hallamshire Hosp, Dept Radiol, Sheffield, England
[5] Univ Sheffield, Insigneo Inst, Sheffield, England
[6] Natl Inst Hlth & Care Res, Sheffield Biomed Res Ctr, Sheffield, England
基金
英国惠康基金;
关键词
systemic sclerosis; pulmonary; Interstitial lung disease; left heart disease; outcomes; INTERSTITIAL LUNG-DISEASE; ARTERIAL-HYPERTENSION; HEART-FAILURE; SURVIVAL; SCLERODERMA; IMPACT;
D O I
10.1016/j.healun.2024.06.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: There are limited data assessing the spectrum of systemic sclerosis-associated pulmonary hypertension (PH). METHODS: Data for 912 systemic sclerosis patients assessed between 2000 and 2020 were retrieved from the Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre (ASPIRE) registry and classified based on 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines and multimodality investigations. RESULTS: Reduction in pulmonary vascular resistance (PVR) diagnostic threshold to > 2 WU resulted in a 19% increase in precapillary PH diagnoses. Patients with PVR <= 2 WU had superior survival to PVR > 2-3 WU which was similar to PVR > 3-4 WU. Survival in pulmonary arterial hypertension (PAH) was superior to PH associated with lung disease. However, patients with mild parenchymal disease on CT had similar characteristics and outcomes to patients without lung disease. Combined pre- and postcapillary PH had significantly poorer survival than isolated postcapillary PH. Patients with mean pulmonary arterial wedge pressure (PAWP) 13-15 mm Hg had similar haemodynamics and left atrial volumes to those with PAWP > 15 mm Hg. Unclassified-PH had more frequently dilated left atria and higher PAWP than PAH. Although Unclassified-PH had a similar survival to No-PH, 36% were subsequently diagnosed with PAH or PH associated with left heart disease. The presence of 2-3 radiological signs of pulmonary veno-occlusive disease was noted in 7% of PAH patients and was associated with worse survival. Improvement in incremental shuttle walking distance of >= 30 m following initiation of PAH therapy was associated with superior survival. PAH patients diagnosed after 2011 had greater use of combination therapy and superior survival. CONCLUSION: A number of systemic sclerosis PH phenotypes can be recognized and characterized using haemodynamics, lung function and multimodality imaging. J Heart Lung Transplant 2024;43:1629-1639 (c) 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
引用
收藏
页码:1629 / 1639
页数:11
相关论文
共 50 条
  • [41] Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
    Christopher P Denton
    Jerome Avouac
    Frank Behrens
    Daniel E Furst
    Ivan Foeldvari
    Marc Humbert
    Doerte Huscher
    Otylia Kowal-Bielecka
    Marco Matucci-Cerinic
    Peter Nash
    Christian F Opitz
    David Pittrow
    Lewis J Rubin
    James R Seibold
    Oliver Distler
    Arthritis Research & Therapy, 13
  • [42] Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia
    Carbone, Roberto G.
    Monselise, Assaf
    Barisione, Emanuela
    Fontana, Vincenzo
    Paredi, Paolo
    Puppo, Francesco
    INTERNAL AND EMERGENCY MEDICINE, 2023, 18 (04) : 1087 - 1093
  • [43] Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
    Bergamasco, Aurore
    Hartmann, Nadine
    Wallace, Laura
    Verpillat, Patrice
    CLINICAL EPIDEMIOLOGY, 2019, 11 : 257 - 273
  • [44] Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study
    Yu-Ping Yuan
    Ping Yuan
    Yi-Liang Su
    Rong Jiang
    Rui Zhang
    Jing He
    Hong-Ling Qiu
    Ci-Jun Luo
    Jin-Ming Liu
    Su-Gang Gong
    Lan Wang
    Qin-Hua Zhao
    Clinical Rheumatology, 2022, 41 : 1675 - 1686
  • [45] Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis
    Morrisroe, Kathleen
    Hansen, Dylan
    Stevens, Wendy
    Ross, Laura
    Sahhar, Joanne
    Ngian, Gene-Siew
    Hill, Catherine
    Host, Lauren
    Walker, Jennifer
    Proudman, Susanna
    Nikpour, Mandana
    RHEUMATOLOGY, 2024,
  • [46] Stress echocardiogram in the early diagnosis of systemic sclerosis-associated pulmonary hypertension
    Callejas Rubio, Jose Luis
    Parra Rosado, Pilar
    Ortego Centeno, Norberto
    MEDICINA CLINICA, 2016, 147 (02): : 91 - 91
  • [47] Systemic sclerosis-associated interstitial lung disease
    Scallan, Ciaran J.
    Collins, Bridget F.
    Raghu, Ganesh
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 487 - 495
  • [48] Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension
    Coghlan, J. G.
    Denton, Christopher P.
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2018, 3 (01) : 30 - 38
  • [49] Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension
    Launay, David
    Sanges, Sebastien
    Sobanski, Vincent
    EUROPEAN RESPIRATORY JOURNAL, 2021, 57 (06)
  • [50] Current treatment of systemic sclerosis-associated interstitial lung disease
    Bes, Cemal
    Cetinkaya, Erdogan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92